We are a team of architects, engineers, scientists.
We believe in science and in service to the others.
We value science through our engagement on creating lab workplace solution and funding support, so that life science companies can focus their time, investment and energy on science.
We are enthusiastic to innovative our work as much as scientists to their discovery!
Dr. Thilo Schröder
Thilo is a board member of Revolution Medicines (NASDAQ: RVMD), PMV Pharma (NASDAQ: PVMP), Circle Pharma, Silverback Therapeutics (NASDAQ: SBTX), MOMA Therapeutics. Past board seats include Blueprint Medicines (NASDAQ: BPMC), Peloton Therapeutics (acquired by Merck) and IDEAYA Biosciences (NASDAQ: IDYA). Thilo is a past board observer of BlackDiamond Therapeutics (NASDAQ: BDTX).
Thilo began his biotech career at the pioneering cancer immunology company Micromet (acquired by Amgen) while studying at Ecole Supérieure de Biotechnologie de Strasbourg, conducted research at the University of Sydney and obtained his Ph.D. from the University of Zurich, focused on protein engineering in the development of Designed Ankyrin Repeat Proteins (DARPins), a technology developed by Molecular Partners (SWX:MOLN).
Dr. Marcel Kucher
He holds a Master's degree in International Management from the French Business School ESCP Europe and London City University, and has completed the International Directors Program at INSEAD.
He speaks four languages and through his professional activities has a large network of alumni and business contacts throughout Europe.
At Superlab Suisse he continues to pursue his passion of filling properties with life.
Our lab management
He now puts his deep knowledge of laboratory needs and dynamics at the service of the Superlab customers as Lab Manager of the Lausanne site.